SHC 014748M
Alternative Names: SH748M; SHC014748MLatest Information Update: 28 Aug 2021
At a glance
- Originator Nanjing Sanhome Pharmaceutical
- Class Antineoplastics; Heterocyclic compounds; Pyrimidines
- Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Follicular lymphoma; Marginal zone B-cell lymphoma
- No development reported Haematological malignancies
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for phase-I development in Haematological-malignancies(Refractory metastatic disease, Second-line therapy or greater) in China (PO, Capsule)
- 14 Jul 2020 Nanjing Sanhome Pharmaceutical plans a phase II trial for Peripheral T-cell lymphoma (Second-line therapy or greater) in August 2020 (NCT04470141)
- 16 Jun 2020 Nanjing Sanhome Pharmaceutical plans a phase II trial in Follicular lymphoma (Second-line therapy or greater) or Marginal zone B-cell lymphoma (Second-line therapy or greater) in China (PO) in June 2020 (NCT04431089)